Title:
ANTIGEN-BINDING DOMAIN, AND POLYPEPTIDE INCLUDING CONVEYING SECTION
Document Type and Number:
WIPO Patent Application WO/2018/097307
Kind Code:
A1
Abstract:
The present invention pertains to: a polypeptide that includes an antigen-binding domain and a conveying section having an inhibitory domain for inhibiting the antigen-binding activity of the antigen-binding domain, and that has a half-life longer than that of the antigen-binding domain when existing alone; a production method and screening method for the polypeptide; a pharmaceutical composition containing the polypeptide; a production method and screening method for a single-domain antibody the antigen-binding activity of which is inhibited by being associated with a specific VL/VH/VHH; and a library of fused polypeptides including a single-domain antibody the antigen-binding activity of which is inhibited by being associated with a specific VL/VH/VHH.
Inventors:
IGAWA TOMOYUKI (JP)
ISHIKAWA HIROYUKI (JP)
HIRONIWA NAOKA (JP)
ISHIKAWA HIROYUKI (JP)
HIRONIWA NAOKA (JP)
Application Number:
PCT/JP2017/042542
Publication Date:
May 31, 2018
Filing Date:
November 28, 2017
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
C12N15/09; A61K38/16; A61K39/395; A61K47/64; A61K47/65; C07K19/00; C40B30/04; C40B40/10; G01N33/15; G01N33/50; G01N33/53; A61P29/00; A61P35/00; A61P37/06
Domestic Patent References:
| WO2010081173A2 | 2010-07-15 | |||
| WO2004044011A2 | 2004-05-27 | |||
| WO2005040229A2 | 2005-05-06 | |||
| WO2002032925A2 | 2002-04-25 | |||
| WO1995001937A1 | 1995-01-19 | |||
| WO2002020565A2 | 2002-03-14 | |||
| WO2003029462A1 | 2003-04-10 | |||
| WO2008016854A2 | 2008-02-07 | |||
| WO2015143414A2 | 2015-09-24 | |||
| WO2009125825A1 | 2009-10-15 | |||
| WO2013128194A1 | 2013-09-06 | |||
| WO2009025846A2 | 2009-02-26 | |||
| WO2015116933A2 | 2015-08-06 | |||
| WO2015048329A2 | 2015-04-02 | |||
| WO2016118629A1 | 2016-07-28 | |||
| WO2016179257A2 | 2016-11-10 | |||
| WO2016179285A1 | 2016-11-10 | |||
| WO2016179335A1 | 2016-11-10 | |||
| WO2016179003A1 | 2016-11-10 | |||
| WO2016046778A2 | 2016-03-31 | |||
| WO2016014974A2 | 2016-01-28 | |||
| WO2010115998A2 | 2010-10-14 | |||
| WO2015046554A1 | 2015-04-02 |
Foreign References:
| JP2012514982A | 2012-07-05 | |||
| JP2015509952A | 2015-04-02 | |||
| JP2010536370A | 2010-12-02 | |||
| US6248516B1 | 2001-06-19 | |||
| US20110123527A1 | 2011-05-26 | |||
| US20160289324A1 | 2016-10-06 | |||
| US20160311903A1 | 2016-10-27 |
Other References:
ORAN ERSTER, JERRY M. THOMAS, JULIANA HAMZAH, ABEER M. JABAIAH, ... PATRICK S. DAUGHERTY: "Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases", JOURNAL OF CONTROLLED RELEASE, vol. 161, no. 3, 23 May 2012 (2012-05-23), pages 804 - 812, XP028409044, DOI: 10.1016/j.jconrel.2012.05.035
JANICE M REICHERTCLARK J ROSENSWEIGLAURA B FADENMATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078, XP002555770, DOI: doi:10.1038/nbt0905-1073
PAVLOU AKBELSEY MJ.: "The therapeutic antibodies market to 2008", EUR. J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396, XP025317626, DOI: doi:10.1016/j.ejpb.2004.11.007
WEINER LMSURANA RWANG S.: "Monoclonal antibodies: versatile platforms for cancer immunotherapy", NAT. REV. IMMUNOL., vol. 10, no. 5, 2010, pages 317 - 327, XP055217481, DOI: doi:10.1038/nri2744
LEWIS GDFIGARI IFENDLY BWONG WLCARTER PGORMAN CSHEPARD HM: "Differential responses of human tumor cell lines to anti-pl 85HER2 monoclonal antibodies", CANCER IMMUNOL. IMMUNOTHERAPY, vol. 37, 1993, pages 255 - 263, XP002961547, DOI: doi:10.1007/BF01518520
DE BONO JSTOLCHER AWFORERO AVANHOVE GFTAKIMOTO CBAUER RJHAMMOND LAPATNAIK AWHITE MLSHEN S: "ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas", CLIN. CANCER RES., vol. 10, no. 22, 2004, pages 7555 - 7565
SATOH MIIDA SSHITARA K.: "Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies", EXPERT OPIN. BIOL. THER., vol. 6, no. 11, 2006, pages 1161 - 1173, XP008078583, DOI: doi:10.1517/14712598.6.11.1161
DESJARLAIS JRLAZAR GAZHUKOVSKY EACHU SY.: "Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective", DRUG DISCOV. TODAY, vol. 12, no. 21-22, 2007, pages 898 - 910, XP022338218, DOI: doi:10.1016/j.drudis.2007.08.009
ALLEY SCOKELEY NMSENTER PD.: "Antibody-drug conjugates: targeted drug delivery for cancer", CURR. OPIN. CHEM. BIOL., vol. 14, no. 4, 2010, pages 529 - 537, XP055042125, DOI: doi:10.1016/j.cbpa.2010.06.170
BAEUERLE PAKUFER PBARGOU R.: "BiTE: Teaching antibodies to engage T-cells for cancer therapy", CURR. OPIN. MOL. THER., vol. 11, no. 1, 2009, pages 22 - 30, XP009151509
LUTTERBUESE RRAUM TKISCHEL RHOFFMANN PMANGOLD SRATTEL BFRIEDRICH MTHOMAS OLORENCZEWSKI GRAU D: "T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells", PROC. NATL. ACAD. SCI. U.S.A., vol. 107, no. 28, 2010, pages 12605 - 12610, XP055067703, DOI: doi:10.1073/pnas.1000976107
RIECHELMANN HSAUTER AGOLZE WHANFT GSCHROEN CHOERMANN KERHARDT TGRONAU S.: "Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma", ORAL ONCOL., vol. 44, no. 9, 2008, pages 823 - 829, XP024341160, DOI: doi:10.1016/j.oraloncology.2007.10.009
TRINH VAHWU WJ.: "Ipilimumab in the treatment of melanoma", EXPERT OPIN. BIOL. THER., 14 April 2012 (2012-04-14)
JUSZCZAK AGUPTA AKARAVITAKI NMIDDLETON MRGROSSMAN A.: "IPILIMUMAB - A NOVEL IMMUNOMODULATING THERAPY CAUSING AUTOIMMUNE HYPOPHYSITIS: A CASE REPORT AND REVIEW", EUR. J. ENDOCRINOL., 10 April 2012 (2012-04-10)
TAKEUCHI TKAMEDA H.: "The Japanese experience with biologic therapies for rheumatoid arthritis", NAT. REV. RHEUMATOL., vol. 6, no. 11, 2010, pages 644 - 652
NAM JLWINTHROP KLVAN VOLLENHOVEN RFPAVELKA KVALESINI GHENSOR EMWORTHY GLANDEWE RSMOLEN JSEMERY P: "Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA", ANN. RHEUM. DIS., vol. 69, no. 6, 2010, pages 976 - 986
KIM SJPARK YHONG HJ.: "Antibody engineering for the development of therapeutic antibodies", MOL. CELLS., vol. 20, no. 1, 2005, pages 17 - 29
DESNOYERS LRVASILJEVA ORICHARDSON JHYANG AMENENDEZ EELIANG TWWONG CBESSETTE PHKAMATH KMOORE SJ: "Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index", SCI TRANSL MED., vol. 5, no. 207, 16 October 2013 (2013-10-16), pages 207ra144, XP055296685, DOI: doi:10.1126/scitranslmed.3006682
POLU KRLOWMAN HB: "Probody therapeutics for targeting antibodies to diseased tissue", EXPERT OPIN BIOL THER., vol. 14, no. 8, August 2014 (2014-08-01), pages 1049 - 53, XP055228738, DOI: doi:10.1517/14712598.2014.920814
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
J. IMMUNOL. METHODS, vol. 324, 2007, pages 13
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
J BIOL CHEM., vol. 263, no. 29, 15 October 1988 (1988-10-15), pages 15064 - 70
METHODS IN MOLECULAR BIOLOGY, vol. 911, 2012, pages 65 - 78
BIOCHIMICA ET BIOPHYSICA ACTA - PROTEINS AND PROTEOMICS, vol. 1764, no. 8, 2006, pages 1307 - 1319
JOURNAL OF APPLIED MICROBIOLOGY, vol. 117, no. 2, 2014, pages 528 - 536
JOURNAL OF BIOMOLECULAR SCREENING, vol. 21, no. 1, 2016, pages 35 - 43
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 24, 2016, pages 12641 - 12657
AIDS, vol. 30, no. 11, 2016, pages 1691 - 1701
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881
METHODS ENZYMOL., vol. 323, 2000, pages 325 - 40
MOL CELL BIOL., vol. 8, 1988, pages 466 - 472
J CLIN INVEST., vol. 32, no. 8, August 1953 (1953-08-01), pages 746 - 768
ANTIBODIES, vol. 4, no. 3, 2015, pages 141 - 156
J PHARM SCI., vol. 97, no. 10, October 2008 (2008-10-01), pages 4167 - 83
ALSO, J INFLAMM (LOND)., vol. 7, 2010, pages 45
NAT REV IMMUNOL., vol. 6, no. 7, July 2006 (2006-07-01), pages 541 - 50
NAT REV DRUG DISCOV., vol. 13, no. 12, December 2014 (2014-12-01), pages 904 - 27
RESPIR RES., vol. 17, 4 March 2016 (2016-03-04), pages 23
DIS MODEL MECH., vol. 7, no. 2, February 2014 (2014-02-01), pages 193 - 203
BIOCHIM BIOPHYS ACTA, vol. 1824, no. 1, January 2012 (2012-01-01), pages 133 - 45
NAT REV CANCER, vol. 3, no. 7, July 2003 (2003-07-01), pages 489 - 501
PNAS, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages 93 - 98
NAT REV DRUG DISCOV, vol. 9, no. 9, September 2010 (2010-09-01), pages 690 - 701
NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 661 - 667
PNAS, vol. 97, 2000, pages 7754 - 7759
BIOCHEMICAL JOURNAL, vol. 426, 2010, pages 219 - 228
BEILSTEIN J NANOTECHNOL., vol. 7, 2016, pages 364 - 373
J. MOL. BIOL., vol. 350, 2005, pages 112 - 125
"GenBank", Database accession no. AB009864
"Current protocols in Molecular Biology", 1987, JOHN WILEY & SONS
NAT BIOTECHNOL., vol. 18, no. 12, December 2000 (2000-12-01), pages 1287 - 92
NUCLEIC ACIDS RES., vol. 34, no. 19, 2006, pages e127
PROC NATL ACAD SCI USA., vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 2806 - 10
PROC NATL ACAD SCI USA., vol. 101, no. 25, 22 June 2004 (2004-06-22), pages 9193 - 8
PROTEIN ENG DES SEL., vol. 21, no. 4, April 2008 (2008-04-01), pages 247 - 55
PROC NATL ACAD SCI USA, vol. 97, no. 20, 26 September 2000 (2000-09-26), pages 10701 - 5
MABS., vol. 2, no. 5, September 2010 (2010-09-01), pages 508 - 18
METHODS MOL BIOL., vol. 911, 2012, pages 183 - 98
THE CHINESE-GERMAN JOURNAL OF CLINICAL ONCOLOGY, vol. 3, no. 2, June 2004 (2004-06-01), pages 78,80
BLOOD., vol. 127, no. 13, 31 March 2016 (2016-03-31), pages 1633 - 41
BLOOD, vol. 127, no. 13, 31 March 2016 (2016-03-31), pages 1633 - 41
J. IMMUNOL. METHODS., vol. 332, no. 1-2, 2008, pages 2 - 9
J. IMMUNOL. METHODS, vol. 247, no. 1-2, 2001, pages 191 - 203
BIOTECHNOL. PROG., vol. 18, no. 2, 2002, pages 212 - 20
MOL. CELL PROTEOMICS, vol. 2, no. 2, 2003, pages 61 - 9
J. IMMUNOL. METHODS., vol. 247, no. 1-2, 2001, pages 191 - 203
JOURNAL OF MOLECULAR BIOLOGY, vol. 302, 2000, pages 899 - 916
See also references of EP 3546574A4
JANICE M REICHERTCLARK J ROSENSWEIGLAURA B FADENMATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078, XP002555770, DOI: doi:10.1038/nbt0905-1073
PAVLOU AKBELSEY MJ.: "The therapeutic antibodies market to 2008", EUR. J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396, XP025317626, DOI: doi:10.1016/j.ejpb.2004.11.007
WEINER LMSURANA RWANG S.: "Monoclonal antibodies: versatile platforms for cancer immunotherapy", NAT. REV. IMMUNOL., vol. 10, no. 5, 2010, pages 317 - 327, XP055217481, DOI: doi:10.1038/nri2744
LEWIS GDFIGARI IFENDLY BWONG WLCARTER PGORMAN CSHEPARD HM: "Differential responses of human tumor cell lines to anti-pl 85HER2 monoclonal antibodies", CANCER IMMUNOL. IMMUNOTHERAPY, vol. 37, 1993, pages 255 - 263, XP002961547, DOI: doi:10.1007/BF01518520
DE BONO JSTOLCHER AWFORERO AVANHOVE GFTAKIMOTO CBAUER RJHAMMOND LAPATNAIK AWHITE MLSHEN S: "ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas", CLIN. CANCER RES., vol. 10, no. 22, 2004, pages 7555 - 7565
SATOH MIIDA SSHITARA K.: "Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies", EXPERT OPIN. BIOL. THER., vol. 6, no. 11, 2006, pages 1161 - 1173, XP008078583, DOI: doi:10.1517/14712598.6.11.1161
DESJARLAIS JRLAZAR GAZHUKOVSKY EACHU SY.: "Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective", DRUG DISCOV. TODAY, vol. 12, no. 21-22, 2007, pages 898 - 910, XP022338218, DOI: doi:10.1016/j.drudis.2007.08.009
ALLEY SCOKELEY NMSENTER PD.: "Antibody-drug conjugates: targeted drug delivery for cancer", CURR. OPIN. CHEM. BIOL., vol. 14, no. 4, 2010, pages 529 - 537, XP055042125, DOI: doi:10.1016/j.cbpa.2010.06.170
BAEUERLE PAKUFER PBARGOU R.: "BiTE: Teaching antibodies to engage T-cells for cancer therapy", CURR. OPIN. MOL. THER., vol. 11, no. 1, 2009, pages 22 - 30, XP009151509
LUTTERBUESE RRAUM TKISCHEL RHOFFMANN PMANGOLD SRATTEL BFRIEDRICH MTHOMAS OLORENCZEWSKI GRAU D: "T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells", PROC. NATL. ACAD. SCI. U.S.A., vol. 107, no. 28, 2010, pages 12605 - 12610, XP055067703, DOI: doi:10.1073/pnas.1000976107
RIECHELMANN HSAUTER AGOLZE WHANFT GSCHROEN CHOERMANN KERHARDT TGRONAU S.: "Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma", ORAL ONCOL., vol. 44, no. 9, 2008, pages 823 - 829, XP024341160, DOI: doi:10.1016/j.oraloncology.2007.10.009
TRINH VAHWU WJ.: "Ipilimumab in the treatment of melanoma", EXPERT OPIN. BIOL. THER., 14 April 2012 (2012-04-14)
JUSZCZAK AGUPTA AKARAVITAKI NMIDDLETON MRGROSSMAN A.: "IPILIMUMAB - A NOVEL IMMUNOMODULATING THERAPY CAUSING AUTOIMMUNE HYPOPHYSITIS: A CASE REPORT AND REVIEW", EUR. J. ENDOCRINOL., 10 April 2012 (2012-04-10)
TAKEUCHI TKAMEDA H.: "The Japanese experience with biologic therapies for rheumatoid arthritis", NAT. REV. RHEUMATOL., vol. 6, no. 11, 2010, pages 644 - 652
NAM JLWINTHROP KLVAN VOLLENHOVEN RFPAVELKA KVALESINI GHENSOR EMWORTHY GLANDEWE RSMOLEN JSEMERY P: "Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA", ANN. RHEUM. DIS., vol. 69, no. 6, 2010, pages 976 - 986
KIM SJPARK YHONG HJ.: "Antibody engineering for the development of therapeutic antibodies", MOL. CELLS., vol. 20, no. 1, 2005, pages 17 - 29
DESNOYERS LRVASILJEVA ORICHARDSON JHYANG AMENENDEZ EELIANG TWWONG CBESSETTE PHKAMATH KMOORE SJ: "Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index", SCI TRANSL MED., vol. 5, no. 207, 16 October 2013 (2013-10-16), pages 207ra144, XP055296685, DOI: doi:10.1126/scitranslmed.3006682
POLU KRLOWMAN HB: "Probody therapeutics for targeting antibodies to diseased tissue", EXPERT OPIN BIOL THER., vol. 14, no. 8, August 2014 (2014-08-01), pages 1049 - 53, XP055228738, DOI: doi:10.1517/14712598.2014.920814
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
J. IMMUNOL. METHODS, vol. 324, 2007, pages 13
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
J BIOL CHEM., vol. 263, no. 29, 15 October 1988 (1988-10-15), pages 15064 - 70
METHODS IN MOLECULAR BIOLOGY, vol. 911, 2012, pages 65 - 78
BIOCHIMICA ET BIOPHYSICA ACTA - PROTEINS AND PROTEOMICS, vol. 1764, no. 8, 2006, pages 1307 - 1319
JOURNAL OF APPLIED MICROBIOLOGY, vol. 117, no. 2, 2014, pages 528 - 536
JOURNAL OF BIOMOLECULAR SCREENING, vol. 21, no. 1, 2016, pages 35 - 43
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 24, 2016, pages 12641 - 12657
AIDS, vol. 30, no. 11, 2016, pages 1691 - 1701
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881
METHODS ENZYMOL., vol. 323, 2000, pages 325 - 40
MOL CELL BIOL., vol. 8, 1988, pages 466 - 472
J CLIN INVEST., vol. 32, no. 8, August 1953 (1953-08-01), pages 746 - 768
ANTIBODIES, vol. 4, no. 3, 2015, pages 141 - 156
J PHARM SCI., vol. 97, no. 10, October 2008 (2008-10-01), pages 4167 - 83
ALSO, J INFLAMM (LOND)., vol. 7, 2010, pages 45
NAT REV IMMUNOL., vol. 6, no. 7, July 2006 (2006-07-01), pages 541 - 50
NAT REV DRUG DISCOV., vol. 13, no. 12, December 2014 (2014-12-01), pages 904 - 27
RESPIR RES., vol. 17, 4 March 2016 (2016-03-04), pages 23
DIS MODEL MECH., vol. 7, no. 2, February 2014 (2014-02-01), pages 193 - 203
BIOCHIM BIOPHYS ACTA, vol. 1824, no. 1, January 2012 (2012-01-01), pages 133 - 45
NAT REV CANCER, vol. 3, no. 7, July 2003 (2003-07-01), pages 489 - 501
PNAS, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages 93 - 98
NAT REV DRUG DISCOV, vol. 9, no. 9, September 2010 (2010-09-01), pages 690 - 701
NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 661 - 667
PNAS, vol. 97, 2000, pages 7754 - 7759
BIOCHEMICAL JOURNAL, vol. 426, 2010, pages 219 - 228
BEILSTEIN J NANOTECHNOL., vol. 7, 2016, pages 364 - 373
J. MOL. BIOL., vol. 350, 2005, pages 112 - 125
"GenBank", Database accession no. AB009864
"Current protocols in Molecular Biology", 1987, JOHN WILEY & SONS
NAT BIOTECHNOL., vol. 18, no. 12, December 2000 (2000-12-01), pages 1287 - 92
NUCLEIC ACIDS RES., vol. 34, no. 19, 2006, pages e127
PROC NATL ACAD SCI USA., vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 2806 - 10
PROC NATL ACAD SCI USA., vol. 101, no. 25, 22 June 2004 (2004-06-22), pages 9193 - 8
PROTEIN ENG DES SEL., vol. 21, no. 4, April 2008 (2008-04-01), pages 247 - 55
PROC NATL ACAD SCI USA, vol. 97, no. 20, 26 September 2000 (2000-09-26), pages 10701 - 5
MABS., vol. 2, no. 5, September 2010 (2010-09-01), pages 508 - 18
METHODS MOL BIOL., vol. 911, 2012, pages 183 - 98
THE CHINESE-GERMAN JOURNAL OF CLINICAL ONCOLOGY, vol. 3, no. 2, June 2004 (2004-06-01), pages 78,80
BLOOD., vol. 127, no. 13, 31 March 2016 (2016-03-31), pages 1633 - 41
BLOOD, vol. 127, no. 13, 31 March 2016 (2016-03-31), pages 1633 - 41
J. IMMUNOL. METHODS., vol. 332, no. 1-2, 2008, pages 2 - 9
J. IMMUNOL. METHODS, vol. 247, no. 1-2, 2001, pages 191 - 203
BIOTECHNOL. PROG., vol. 18, no. 2, 2002, pages 212 - 20
MOL. CELL PROTEOMICS, vol. 2, no. 2, 2003, pages 61 - 9
J. IMMUNOL. METHODS., vol. 247, no. 1-2, 2001, pages 191 - 203
JOURNAL OF MOLECULAR BIOLOGY, vol. 302, 2000, pages 899 - 916
See also references of EP 3546574A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF:
Previous Patent: ELECTRIC BOOSTER
Next Patent: LIGAND-BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY
Next Patent: LIGAND-BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY